Sea option becoming viable for drug shipments

Trouble is brewing above. Though beleaguered airlines currently have plenty of room for drug cargo--and even appear to be catering to the drug business, as we've reported--they are cutting capacity. As the improving economy re-energizes global commerce in all industries, drug space on aircraft may become hard to find, says Kevin O'Donnell, a director at Tegrant Corp., in Pharmaceutical Commerce magazine.

A dozen vaccines are nearing approval for distribution in developing and middle-income countries, according to the Partnership for Appropriate Technology in Healthcare. And vaccine shipments are getting fatter: PATH projects a five-fold increase in cubic volume for three of these, thanks to the packaging of fewer doses per vial to minimize spoilage. In addition, temperature-sensitive biologics as a whole are growing nicely and projected to represent half of drug approvals by 2015.

These and other elements, when combined, will cause a cargo crunch. "If the airlines move too cautiously, capacity will become an issue," writes O'Donnell. "Even though pharmaceutical freight has a higher priority index than general cargo, there is a real potential that demand could exceed available capacity."

A transport alternative to consider is sea shipment, he says. "While the risk of putting multi-million dollar shipments of brand equity on the waves is not a consideration most pharma companies have entertained in the past, developing technologies for refrigerated sea containers and logistics" makes it worth a second look, according to O'Donnell. He provides a biopharma to-do list to help manufacturers prepare for the coming crunch.

- here's the article

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.